The content on this site is intended for healthcare professionals only
Dr Fehrenbacher speaks at a SABCS 2017 press session about data from the randomised, phase III NSABP-B-47 clinical trial.
Adding trastuzumab (Herceptin) to standard adjuvant chemotherapy did not improve invasive disease–free survival for patients with early-stage breast cancer found to have low levels of HER2, as defined as immunohistochemistry (IHC) 1 or 2 and/or in situ hybridization (ISH) negative.
Watch the video interview for more.
The added value of integrative medicine
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
Multiple myeloma In Rwanda: The need for further research
GIST tumours and soft tissue sarcomas
Genomic testing: Awareness and effective communication between healthcare professionals and patients
Advancing breast cancer treatment in Uganda by improving molecular testing
Somatic mutation profile of breast cancer in Uganda
The current status of multiple myeloma diagnosis and treatment
